Scarica l'app Stockscreener
0.691
1.38%
-0.0097
Pre-mercato:
.69
-0.001
-0.14%
Precedente Chiudi:
$0.7007
Aprire:
$0.71
Volume 24 ore:
195.97K
Relative Volume:
0.05
Capitalizzazione di mercato:
$5.14M
Reddito:
-
Utile/perdita netta:
$-16.28M
Rapporto P/E:
-0.0497
EPS:
-13.91
Flusso di cassa netto:
$-13.75M
1 W Prestazione:
+0.03%
1M Prestazione:
-13.52%
6M Prestazione:
-72.14%
1 anno Prestazione:
-88.52%
Intervallo 1D:
$0.691
$0.735
Intervallo di 1 settimana:
$0.65
$0.735
Portata 52W:
$0.65
$7.50
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Nome
Pasithea Therapeutics Corp
Settore
Industria
Telefono
(702) 514-4174
Indirizzo
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Confronta KTTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
0.691 | 5.14M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
What analysts say about Pasithea Therapeutics Corp. stockConsistently exceptional gains - Jammu Links News
Why Pasithea Therapeutics Corp. stock attracts strong analyst attentionROI Focused Stock Calls - Newser
How Pasithea Therapeutics Corp. Equity Warrant stock performs during market volatility200 Percent Gain Alert - Newser
How Pasithea Therapeutics Corp. stock performs during market volatilityAI Powered Stock Call - Newser
What makes Pasithea Therapeutics Corp. Equity Warrant stock price move sharplyHigh Return Investment Tips - Newser
Why Pasithea Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionFree Smart Investment Opportunities - Newser
What makes Pasithea Therapeutics Corp. stock price move sharplyDaily Stock Radar - Newser
Pasithea Therapeutics schedules 2025 annual meeting for September 3 By Investing.com - Investing.com Nigeria
Pasithea Sets Deadline for Shareholder Proposals - TipRanks
Pasithea Therapeutics schedules 2025 annual meeting for September 3 - Investing.com
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board - GlobeNewswire
Nature Journal Author Joins Pasithea to Advance Revolutionary IBD Treatment Research - Stock Titan
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Pasithea reports promising phase 1 results for cancer drug By Investing.com - Investing.com South Africa
Pasithea reports promising phase 1 results for cancer drug - Investing.com
Pasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025 - Nasdaq
Pasithea Therapeutics Presents Updated Interim Data from - GlobeNewswire
Breakthrough Cancer Drug Shows 15% Tumor Shrinkage in Melanoma and Pancreatic Cancer Patients in Phase 1 Trial - Stock Titan
Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com
Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq
Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire
Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance
Pasithea Therapeutics CEO sells shares worth $792 - Investing.com
Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com
Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire
Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan
Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks
Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq
Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire
Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance
Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India
Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times
Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal
$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan
Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Pasithea Therapeutics Corp Azioni (KTTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Pasithea Therapeutics Corp Azioni (KTTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Marques Tiago | Chief Executive Officer |
May 12 '25 |
Sale |
0.82 |
960 |
792 |
40,001 |
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):